Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page now displays a new revision label (v3.6.6) replacing the previous v3.6.5, indicating a new build of the site. This reflects a maintenance/version update rather than substantive changes to study content or user-facing features.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays Revision: v3.6.5, indicating an updated site deployment. The previous Revision: v3.6.4 label has been superseded.SummaryDifference0.1%

- Check32 days agoChange DetectedRemoved the reference to the 2012 NEJM article Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. This background citation supported contextual information but is not part of the study's design, results, or eligibility details.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page shows a new revision tag v3.6.4 replacing the previous v3.6.3, indicating a minor patch or update to the page or system without visible content changes.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page’s revision indicator was updated to v3.6.3, indicating a minor site update. This does not modify the study details or related data.SummaryDifference0.1%

- Check68 days agoChange DetectedA classic NEJM trial reference on preoperative chemotherapy plus surgery for NSCLC was added, and the site revision tag was updated from v3.6.0 to v3.6.2.SummaryDifference0.1%

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.